Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma | Breast Cancer | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
Collaborative Group on Hormonal Factors in Breast Cancer.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.  Lancet.1997;350:1047-1059.Google Scholar
2.
Rossouw JE, Anderson GL, Prentice RL.  et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.  JAMA.2002;288:321-333.Google Scholar
3.
Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women.  Cancer.2000;88:2570-2577.Google Scholar
4.
Newcomer LM, Newcomb PA, Daling JR, Yasui Y, Potter JD. Post-menopausal hormone use and risk of breast cancer by histologic type [abstract].  Am J Epidemiol.1999;149:S79.Google Scholar
5.
Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer.  JAMA.2002;287:734-741.Google Scholar
6.
Newcomb PA, Titus-Ernstoff L, Egan KM.  et al.  Postmenopausal estrogen and progestin use in relation to breast cancer risk.  Cancer Epidemiol Biomarkers Prev.2002;11:593-600.Google Scholar
7.
Daling JR, Malone KE, Doody DR.  et al.  Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.  Cancer.2002;95:2455-2464.Google Scholar
8.
Kennedy DL, Baum C, Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time.  Obstet Gynecol.1985;65:441-446.Google Scholar
9.
Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86.  Am J Public Health.1988;78:1479-1481.Google Scholar
10.
Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992.  Obstet Gynecol.1995;85:6-10.Google Scholar
11.
Carr BR. HRT management: the American experience.  Eur J Obstet Gynecol Reprod Biol.1996;64(suppl):S17-S20.Google Scholar
12.
Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study.  Am J Epidemiol.1997;145:536-545.Google Scholar
13.
Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tuchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: correlation of histopathology and prognostic factors.  Ann Surg.1993;218:13-21.Google Scholar
14.
Du Toit RS, Locker AP, Ellis IO.  et al.  An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast.  Eur J Surg Oncol.1991;17:251-257.Google Scholar
15.
Dixon J, Anderson T, Page D, Lee D, Duffy S. Infiltrating lobular carcinoma of the breast.  Histopathology.1982;6:149-161.Google Scholar
16.
Yeatman TJ, Cantor AB, Smith TJ.  et al.  Tumor biology of infiltrating lobular carcinoma: implications for management.  Ann Surg.1995;222:549-559.Google Scholar
17.
Silverstein MJ, Lewinsky BS, Waisman JR.  et al.  Infiltrating lobular carcinoma: is it different from infiltrating duct carcinoma?  Cancer.1994;73:1673-1677.Google Scholar
18.
Davis RP, Nora PF, Kooy RG, Hines JR. Experience with lobular carcinoma of the breast: emphasis on recent aspects of management.  Arch Surg.1979;114:485-488.Google Scholar
19.
Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women.  Cancer.2000;88:2561-2569.Google Scholar
20.
National Cancer Institute.  About SEER. Available at: http://seer.cancer.gov/about/. Accessibility verified February 10, 2003.
21.
National Cancer Institute.  SEER Data Quality. Available at: http://seer.cancer.gov/about/quality.html. Accessibility verified February 10, 2003.
22.
National Cancer Institute.  Characteristics of the SEER Population Compared with the Total United States Population. Available at: http://www.seer.cancer.gov/registries/characteristics.html. Accessibility verified February 10, 2003.
23.
Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models.  Psychol Bull.1995;118:392-404.Google Scholar
24.
Skaane P, Skjorten F. Ultrasonographic evaluation of invasive lobular carcinoma.  Acta Radiol.1999;40:369-375.Google Scholar
25.
Evans N, Lyons K. The use of ultrasound in the diagnosis of invasive lobular carcinoma of the breast less than 10 mm in size.  Clin Radiol.2000;55:261-263.Google Scholar
26.
Weinstein SP, Orel SG, Heller R.  et al.  MR imaging of the breast in patients with invasive lobular carcinoma.  AJR Am J Roentgenol.2001;176:399-406.Google Scholar
27.
Munot K, Dall B, Achuthan R, Parkin G, Lane S, Horgan K. Role of magnetic resonance imaging in the diagnosis and single-stage surgical resection of invasive lobular carcinoma of the breast.  Br J Surg.2002;89:1296-1301.Google Scholar
28.
Ross RK, Paganini-Hill A, Gerkins VR.  et al.  A case-control study of menopausal estrogen therapy and breast cancer.  JAMA.1980;243:1635-1639.Google Scholar
Brief Report
March 19, 2003

Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma

Author Affiliations

Author Affiliations: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Wash (Drs Li, Anderson, and Daling); Department of Surgery, School of Medicine, University of Washington, Seattle (Drs Anderson and Moe).

JAMA. 2003;289(11):1421-1424. doi:10.1001/jama.289.11.1421
Abstract

Context Research has suggested that use of combined estrogen and progestin hormone replacement therapy (CHRT) increases breast cancer risk and that CHRT use is more strongly associated with the risk of invasive lobular breast carcinoma than that of invasive ductal carcinoma. Lobular carcinoma is less common than ductal carcinoma but can be more difficult to diagnose because of its subtle elusive infiltrative pattern.

Objective To evaluate trends in invasive lobular and ductal carcinoma incidence rates from 1987 through 1999, during which time use of CHRT increased in the United States.

Design Descriptive epidemiologic study.

Setting Nine cancer registries that participate in the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute and that cover Atlanta, Ga; Detroit, Mich; San Francisco-Oakland, Calif; Seattle, Wash; and Connecticut, Hawaii, Iowa, New Mexico, and Utah.

Population Women 30 years of age and older residing in the areas covered by the 9 SEER registries.

Main Outcome Measures Proportional changes in incidence rates of invasive lobular and ductal carcinoma among women with no prior history of breast cancer.

Results A total of 190 458 women were included in this analysis who were identified through the registries as having invasive breast cancer; 7682 of the 198 140 potentially eligible women (ie, those identified as not having in situ breast cancer) were excluded from this analysis because stage of cancer was unknown. Invasive breast cancer incidence rates adjusted for age and for SEER historic stage increased 1.04-fold (95% confidence interval [CI], 1.004-1.07) from 1987-1999 (206.7/100 000 to 214.1/100 000, age-adjusted). However, incidence rates of tumors classified as lobular increased 1.52-fold (95% CI, 1.42-1.63), and those classified as mixed ductal-lobular increased 1.96-fold (95% CI, 1.80-2.14); rates of these types combined increased 1.65-fold (95% CI, 1.55-1.78) (19.8/100 000 to 33.4/100 000, age-adjusted). In contrast, ductal carcinoma rates remained largely constant (153.8/100 000 to 155.3/100 000, age-adjusted; proportional change, 1.03 [95% CI, 0.99-1.06]). The proportion of breast cancers with a lobular component increased from 9.5% in 1987 to 15.6% in 1999.

Conclusions Ductal carcinoma incidence rates remained essentially constant from 1987-1999 while lobular carcinoma rates increased steadily. This increase presents a clinical challenge given that lobular carcinoma is more difficult to detect than ductal carcinoma by both physical examination and mammography.

×